105 related articles for article (PubMed ID: 10023325)
1. Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC).
Boni C; Savoldi L; Bisagni G; Ceci G; Crinò L; De Lisi V; Di Costanzo F; Lasagni L; Manenti AL; Moretti G; Rondini E; Sassi M; Zadro A
Eur J Cancer; 1998 Nov; 34(12):1974-6. PubMed ID: 10023325
[TBL] [Abstract][Full Text] [Related]
2. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
Gebbia V; Galetta D; Riccardi F; Gridelli C; Durini E; Borsellino N; Gebbia N; Valdesi M; Caruso M; Valenza R; Pezzella G; Colucci G;
Lung Cancer; 2002 Aug; 37(2):179-87. PubMed ID: 12140141
[TBL] [Abstract][Full Text] [Related]
3. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
Gridelli C; Perrone F; Palmeri S; D'Aprile M; Cognetti F; Rossi A; Gebbia V; Pepe R; Veltri E; Airoma G; Russo A; Incoronato P; Scinto AF; Palazzolo G; Natali M; Leonardi V; Gallo C; De Placido S; Bianco AR
Ann Oncol; 1996 Oct; 7(8):821-6. PubMed ID: 8922196
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
[TBL] [Abstract][Full Text] [Related]
5. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer.
Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Saijo N
Eur J Cancer; 1991; 27(5):571-5. PubMed ID: 1647183
[TBL] [Abstract][Full Text] [Related]
6. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study.
Jelić S; Mitrović L; Radosavljević D; Elezar E; Babović N; Kovcin V; Tomasević Z; Kovacević S; Gavrilović D; Radulović S
Lung Cancer; 2001 Oct; 34(1):1-13. PubMed ID: 11557107
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Crinò L; Clerici M; Figoli F; Carlini P; Ceci G; Cortesi E; Carpi A; Santini A; Di Costanzo F; Boni C
Ann Oncol; 1995 Apr; 6(4):347-53. PubMed ID: 7619749
[TBL] [Abstract][Full Text] [Related]
8. Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research.
Crinò L; Clerici M; Figoli F; Barduagni M; Carlini P; Ceci G; Cortesi E; Carpi A; Santini A; Di Costanzo F
Lung Cancer; 1995 Apr; 12 Suppl 1():S125-32. PubMed ID: 7551920
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
Fukuoka M; Masuda N; Furuse K; Negoro S; Takada M; Matsui K; Takifuji N; Kudoh S; Kawahara M; Ogawara M
J Clin Oncol; 1991 Apr; 9(4):606-13. PubMed ID: 1648597
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
Baldini E; Tibaldi C; Ardizzoni A; Salvati F; Antilli A; Portalone L; Barbera S; Romano F; De Marinis F; Migliorino MR; Noseda MA; Borghini U; Crippa M; Ferrara G; Raimondi M; Fioretti M; Bandera M; Pennucci MC; Galeasso G; Cacciani GC; Lepidini G; Sunseri G; Lanfranco C; Rinaldi M; Rosso R
Br J Cancer; 1998 Jun; 77(12):2367-70. PubMed ID: 9649160
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Segawa Y; Kiura K; Takigawa N; Kamei H; Harita S; Hiraki S; Watanabe Y; Sugimoto K; Shibayama T; Yonei T; Ueoka H; Takemoto M; Kanazawa S; Takata I; Nogami N; Hotta K; Hiraki A; Tabata M; Matsuo K; Tanimoto M
J Clin Oncol; 2010 Jul; 28(20):3299-306. PubMed ID: 20530281
[TBL] [Abstract][Full Text] [Related]
12. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.
Kubota K; Watanabe K; Kunitoh H; Noda K; Ichinose Y; Katakami N; Sugiura T; Kawahara M; Yokoyama A; Yokota S; Yoneda S; Matsui K; Kudo S; Shibuya M; Isobe T; Segawa Y; Nishiwaki Y; Ohashi Y; Niitani H;
J Clin Oncol; 2004 Jan; 22(2):254-61. PubMed ID: 14722033
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group.
González Barón M; Feliu J; Espinosa E; García Girón C; Blanco E; Garrido P; Colmenarejo A; Ordóñez A; Moyano A; de la Gándara I
Ann Oncol; 1994 Apr; 5(4):323-7. PubMed ID: 8075028
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer. Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin.
González Barón M; Artal A; Garrido P; García Girón C; Ordóñez A; Feliu J; Berrocal A; Barón JM
Am J Clin Oncol; 1993 Aug; 16(4):310-4. PubMed ID: 8392287
[TBL] [Abstract][Full Text] [Related]
15. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results.
Tejedor M; Valerdi JJ; López R; Domínguez MA; Arias F; Illarramendi JJ; Martínez E
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):813-8. PubMed ID: 7860393
[TBL] [Abstract][Full Text] [Related]
16. [A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer].
Fujii M; Kiura K; Okabe K; Toki H; Kimura M
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2676-81. PubMed ID: 2820312
[TBL] [Abstract][Full Text] [Related]
17. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
18. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer.
Klastersky J; Sculier JP; Ries F; Dabouis G; Libert P; Schmerber J; Thiriaux J; Berchier MC; Bureau G; Van Cutsem O
Lung Cancer; 1994 Dec; 11(5-6):373-84. PubMed ID: 7704494
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.
Burkes RL; Ginsberg RJ; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Cooper JD
J Clin Oncol; 1992 Apr; 10(4):580-6. PubMed ID: 1312587
[TBL] [Abstract][Full Text] [Related]
20. [Activity of toremifene plus mitomycin, vindesin and cisplatin regimen in unresectable non-small cell lung cancer].
Zhou CC; Zhang J; Zheng D; Lu MJ; Lu B; Xu JF
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Aug; 27(8):546-8. PubMed ID: 15388005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
